Payment overview · 2025
General Payments
$828.15
30 reported records · 13 companies
Healthcare provider profile · identity verified
Zareena Abbas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHICAGO, IL · NPI 1427078872
Verified facts
What the public records show
CMS Open Payments records show Zareena Abbas, MD received $828.15 in general payments during 2025 across 30 reported records.
Abbott Laboratories accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $151.21 | 18.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $140.86 | 17.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $86.87 | 10.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.03 | 8.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.32 | 8.1% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $63.58 | 7.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.00 | 7.6% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.96 | 7.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.94 | 4.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.13 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.91 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.22 | 2.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $20.12 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $828.15 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $151.21 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $140.86 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $86.87 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.87 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $63.58 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.00 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $57.96 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $46.64 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 238 | 75 |
| Losartan Potassium | Losartan Potassium | 181 | 50 |
| Metformin Hcl | Metformin Hcl | 174 | 50 |
| Gabapentin | Gabapentin | 168 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 165 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 164 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 49 |
| Jardiance | Empagliflozin | 131 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 102 | 32 |
| Enalapril Maleate | Enalapril Maleate | 97 | 27 |
| Lisinopril | Lisinopril | 97 | 29 |
| Lovastatin | Lovastatin | 97 | 32 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 95 | 13 |
| Carvedilol | Carvedilol | 94 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 24 |
| Simvastatin | Simvastatin | 91 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 28 |
| Omeprazole | Omeprazole | 85 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 81 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 35 |
| Clonazepam | Clonazepam | 78 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 17 |
| Glimepiride | Glimepiride | 69 | 20 |
| Meloxicam | Meloxicam | 68 | 24 |
| Tramadol Hcl | Tramadol Hcl | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 60 | 16 |
| Famotidine | Famotidine | 56 | 19 |
| Glipizide | Glipizide | 55 | 21 |
| Januvia | Sitagliptin Phosphate | 52 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 14 |
| Furosemide | Furosemide | 50 | 17 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 11 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 43 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 12 |
| Azithromycin | Azithromycin | 41 | 39 |
| Memantine Hcl | Memantine Hcl | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Naproxen | Naproxen | 33 | 11 |
| Prednisone | Prednisone | 28 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Eliquis | Apixaban | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $828.15 · 30 records | Abbott Laboratories | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, JOURNAVX, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error